Literature DB >> 11091721

T1 Breast Cancer Associated with Von Recklinghausen's Neurofibromatosis.

.   

Abstract

A rare case of breast cancer associated with von Recklinghausen s neurofibromatosis is reported. This case and review of the literature illustrate the problems of clinical diagnosis. A 66-year-old woman who had undergone sigmoidectomy for sigmoid colon cancer two years previously, was admitted to the hospital because of a left breast skinretraction in October, 1998. The patient had von Recklinghausen fs disease (neurofibromatosis type 1). The TNM clinical staging was T1cN0M0. Modified radical mastectomy was performed. The histopathological diagnosis of the breast tumor was invasive ductal carcinoma and the skin tumor was neurofibroma. The pTNM pathological staging was pT1cN1aM0. Among patients similar to our case, almost all were staged higher than T2. This may be because multiple neurofibromas obscure breast mass at palpation, leading to delayed detection of the cancer. Systemic and careful exploration is essential for patients with von Recklinghausen's neurofibromatosis to detect breast cancer at an early stage.

Entities:  

Year:  1999        PMID: 11091721

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  3 in total

1.  Bilateral Breast Cancer with Neurofibromatosis Type 1 Patient: Case Report.

Authors:  Duygu Dursun; Safiye Aktaş; Zekiye Altun; Nur Olgun
Journal:  Eur J Breast Health       Date:  2017-10-01

2.  Contralateral Breast Cancer With Multiple Primary Neoplasms in a Patient With Neurofibromatosis Type 1: A Case Report and Review of the Literature.

Authors:  Shifaz M Veettil; Jawaid Younus; Edward Yu
Journal:  Cureus       Date:  2021-03-06

3.  Oral metastasis of metaplastic breast carcinoma in a patient with neurofibromatosis 1.

Authors:  Ana Paula Molina Vivas; Luana Eschholz Bomfin; Clovis Antonio Lopes Pinto; Ulisses Ribaldo Nicolau; Fabio Abreu Alves
Journal:  Case Rep Oncol Med       Date:  2014-04-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.